The world's top intensive care agency recommends that patients with severe neo-COVID-19 infections do not use remdesivir

Jozef Kesecioglu, head of the European EsICM, opposes Gilead's Veklury as a routine treatment for patients infected with COVID-19 in the intensive care unit.
photo source: Kesecioglu says the antiviral drug remdesivir has little effect on patients with COVID-19, according to the WHO's new Solidarity trial study.
photo source: fundacionfemeba.org Kesecioglu says it will further discuss remdesivir in a scientific paper on COVID-19 therapy, which is expected to be published in January and is currently being prepared with another intensive care institution, Society of Critical Care Medicine.
the European Union has signed a 1 billion euro deal with Gilead to buy remdesivir for 2,070 euros per course of treatment.
deal did not force European countries to buy remdesivir, but even after the WHO results came out, governments decided to place large orders, and Germany bought a large number in November, saying the drug was useful, especially in the early stages of the disease.
Kesecioglu said there was not enough available data on when remdesivir might work or for which patients, and that its regular use in intensive care units was not encouraged.